Simulating extractables and leachables in biopharmaceutical manufacturing to support safety assessment
Maximilian Bossong1, Armin Hauk2, Ina Pahl2
1Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany; Sartorius Stedim Cellca GmbH, Marie-Goeppert-Mayer-Straße, 89081 Ulm, Germany.
Abstract:
The use of single-use systems in the manufacturing of biopharmaceuticals raises concerns about the accumulation of process equipment-related leachables in their production and purification processes. However, this risk is mitigated by effective sinks in the manufacturing processes and dilution of product flow, for example, in tangential-flow-filtration. This paper presents a modeling approach that combines the release and adsorption of compounds with dynamic process conditions of biopharmaceutical processes. These calculations help assess process criticality by identifying sources but also low-risk processes and components regarding extractables and leachables accumulation. This approach can significantly reduce the necessity for resource-intensive practical testing, such as leachable studies, which may be impractical from an analytical perspective due to the complex matrices in biopharmaceutical process streams.
More Related Videos
11:27A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
05:47In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
Related Concept Videos
Clinically Relevant Drug Product Specifications: Methods of Establishment
Bioequivalence studies: Biowaivers
In Vitro Drug Release Testing: Overview, Development and Validation
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Drug Products: Biologics, Biosimilars and Interchangeables
